Pan-AKT Inhibitor Tumor Agnostic Targeting was Safe and Effective in Phase One Study BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT i
Pan-AKT Inhibitor Tumor Agnostic Targeting was Safe and Effective in Phase One Study
BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT inhibitor ipatasertib in a phase one study reported at the 2022 EORTC—NCI—AACR symposium on Molecular Targets and Cancer Therapeutics.
Nearly a quarter of the patients treated with the AKT blocker had their tumors shrink. These included patients with breast, endometrial cancer and salivary gland cancers. And tumors remained stable in just over half of the remaining patients.
The first author at the Barcelona symposium, Kevin Kalinsky MD MS, Director of Breast Medical Oncology, Emory University at Winship Cancer Institute, Hematology and Medical Oncology, Atlanta, USA talks with Peter Goodwin.
Related Episodes
AUDIO JOURNAL OF ONCOLOGY – ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy
ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy BARCELONA, Spain—Findings from a study of a new investigational therapy targeting the ROS-1 receptor tyrosine
AUDIO JOURNAL OF ONCOLOGY—MYC-Targeted Drug Had Excellent Safety And Solid Tumor Responses
BARCELONA, Spain—Although having a mutated MYC molecule is a distinguishing molecular factor in many solid tumors it has been considered “undruggable” — having a shortage of potential and
AUDIO JOURNAL OF ONCOLOGY—Glioma in Adults: Next Generation Sequencing Validates BRAF Targeting
BARCELONA, Spain—Next generation sequencing is now an essential part of care for glioma in adults, according to research on BRAF targeting as treatment for this disease reported at the 2022 EORTC-NCI-